BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
Subscribe To Our Newsletter & Stay Updated
